TEAMSTA Severe Hypertension Study

calendar
14 Dec, 10

TEAMSTA Severe Hypertension Study

Telmisartan 80 mg plus amlodipine 10 mg superior to respective monotherapies in severe hypertension: TEAMSTA severe hypertension study

Aim

To determine efficacy and tolerability of single pill combination of telmisartan 80 mg/amlodipine 10 mg vs respective monotherapies in patients with severe hypertension.

Study Patients

Patients with severe hypertension [BP >180/95 mmHg ] ( N= 858)

Study Groups

Telmisartan 80 mg/Amlodipine 10 mg (T 80 mg/A 10 mg) (n=421)

Amlodipine 10 mg (A 10 mg) (n=220)

Telmisartan 80 mg (T 80 mg) (n=217)

Study Duration

8 weeks

Results

Significantly greater BP reduction with T 80/A 10 observed as early as 1 week, effect sustained throughout 8 weeks

Greater SBP reduction was observed with T 80/A 10 Versus A 10 and T 80 irrespective of baseline BP

Greater percentage of patients receiving combination therapy achieved robust reduction in SBP versus respective monotherapies

Greater percentage of patients achieved BP goals with combination therapy as compared to respective monotherapies

SBP reductions were greater in T80/A10 group across different subpopulations as compared to respective monotherapies

T80/A10 was as well tolerated as individual monotherapies

Conclusion

As compared to individual monotherapies, treatment of severe hypertensives with a single-pill combination of Telmisartan 80 mg/Amlodipine 10 mg resulted in -

  • Significantly greater BP reduction; obtained as early as one week of treatment
  • Greater SBP reduction irrespective of baseline BP
  • Higher percentage of responders

J Hypertens 2010; 28:e46